Document Detail


Significance of cyclin D1 overexpression in transitional cell carcinomas of the urinary bladder and its correlation with histopathologic features.
MedLine Citation:
PMID:  9024716     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Genetic alterations leading to neoplastic transformation of the urothelium are likely to involve the activation of oncogenes and loss of functional tumor suppressor genes. Cyclin D1 has been implicated as a putative protooncogene whereas mutations of the p53 gene occur frequently in invasive transitional cell carcinomas (TCCs) of the urinary bladder. In this study, cyclin D1 overexpression and nuclear accumulation of p53 were evaluated and the results correlated with histopathologic features. METHODS: TCCs of the urinary bladder from 161 surgical procedures were evaluated for cyclin D1 overexpression and nuclear accumulation of p53. Results were correlated with tumor grade, T classification, and papillary status. Topologic distributions of cyclin D1, p53, and proliferating cellular nuclear antigen (PCNA) were evaluated. Northern blot analysis was performed on selected specimens. RESULTS: Overexpression of cyclin D1 was observed in 47% (24 of 51) of Grade 1 TCCs and 20% (13 of 65) of Grade 2 TCCs but in no Grade 3 TCCs. Approximately 34% (14 of 41) of Ta classified TCCs and 21% (13 of 63) of T1 classified TCCs were immunoreactive for cyclin D1 whereas none of the TCCs beyond T1 was immunoreactive. Overexpression of cyclin D1 was observed only in papillary type TCCs. Results of Northern blot analysis for cyclin D1 were comparable to those of immunohistochemistry. CONCLUSIONS: The observed significant relation between cyclin D1 overexpression and tumor grade/T classification suggests that cyclin D1 may be a useful biologic marker for biopsied materials or urine cytology specimens. The prognostic significance of cyclin D1 overexpression in TCCs remains to be determined.
Authors:
C C Lee; S Yamamoto; K Morimura; H Wanibuchi; N Nishisaka; S Ikemoto; T Nakatani; S Wada; T Kishimoto; S Fukushima
Related Documents :
12036906 - Vhl-mediated hypoxia regulation of cyclin d1 in renal carcinoma cells.
16546976 - Resveratrol inhibits src and stat3 signaling and induces the apoptosis of malignant cel...
19443866 - Pgp 9.5 and cyclin d1 coexpression in cutaneous squamous cell carcinomas.
8626826 - Cyclin d1/prad1 expression in parathyroid adenomas: an immunohistochemical study.
22482976 - Uterine carcinosarcoma associated with pelvic radiotherapy for sacral chordoma: a case ...
20652976 - Insulin-like growth factor-1 receptor inhibitor, amg-479, in cetuximab-refractory head ...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Cancer     Volume:  79     ISSN:  0008-543X     ISO Abbreviation:  Cancer     Publication Date:  1997 Feb 
Date Detail:
Created Date:  1997-03-04     Completed Date:  1997-03-04     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0374236     Medline TA:  Cancer     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  780-9     Citation Subset:  AIM; IM    
Affiliation:
First Department of Pathology, Osaka City University Medical School, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Aged, 80 and over
Blotting, Northern
Carcinoma, Transitional Cell / chemistry*,  pathology
Cell Nucleus / chemistry
Cyclin D1
Cyclins / analysis*
Female
Humans
Immunohistochemistry
Male
Middle Aged
Neoplasm Proteins / analysis*
Oncogene Proteins / analysis*
Proliferating Cell Nuclear Antigen / analysis
Tumor Suppressor Protein p53 / analysis
Urinary Bladder / chemistry
Urinary Bladder Neoplasms / chemistry*,  pathology
Chemical
Reg. No./Substance:
0/Cyclins; 0/Neoplasm Proteins; 0/Oncogene Proteins; 0/Proliferating Cell Nuclear Antigen; 0/Tumor Suppressor Protein p53; 136601-57-5/Cyclin D1

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Tumor angiogenesis correlates with progression after radical prostatectomy but not with pathologic s...
Next Document:  Central neurocytomas.